Quote
—
—
We have scored 67 news catalysts on BIIB (BIIB) over the past 12 months. Coverage across the window leans mixed (average ticker sentiment −0.01). Most of the impact sits in price momentum and forward growth expectations.
Market cap
—
P/E
—
EPS
—
Beta
—
52W range
—
Day range
—
Open
—
Prev close
—
Volume
—
Avg volume
—
Dividend
—
IPO
—
No scored news tagged BIIB or its network in the window yet.
Show more BIIB articles →Analysts publish price targets on BIIB, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
20 analyst price targets from $157 to $300
as of 2026-09-10
The market is 12% below the median target — more cautious than the analysts.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about BIIB — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of BIIB, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for BIIB: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The reconstruction
The price sits at the 10th percentile of published models, 12% below the median, meaning the market largely dismisses the bull case for new growth drivers and leans heavily toward the declining core franchise.
What the disagreement turns on
Whether LEQEMBI's new at-home autoinjector can actually convert the massive untreated Alzheimer's population into paying patients fast enough to offset the MS decline, and the wired data on prescription volumes will be the earliest measurable clue.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
